Amedisys (AMED) Tops Q2 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Amedisys Reports Second Quarter 2018 Financial Results and Updates 2018 Guidance
July 31, 2018 4:10 PM EDTBATON ROUGE, La., July 31, 2018 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month period ended June 30, 2018.
Three Month Periods Ended June 30, 2018 and 2017
Net service revenue increased $36.7Â million to $411.6Â million compared to $374.9Â million in 2017 (1).Net income attributable to Amedisys, Inc. of $33.3Â million compared to $4.5Â million in 2017.Net income attributable to Amedisys, Inc. per diluted share of $0.98 per diluted share compared to $0.13 in 2017.Adjusted Quarterly Results*
Adjusted EBITDA of $49.7Â million compared to $36.1Â million in 2017.Adjusted net service revenue of $413.3Â million compared to... More